ECMO and autoantibody reduction through plasma exchange, experimental therapies not available everywhere, help end an Alabama woman’s five-month medical ordeal.
A two-drug combination therapy for cystic fibrosis is shown to be effective. Triple combination therapy is close behind.
Do you know the warning signs of sepsis? Most Americans don’t … and they should.
A new UAB study will investigate the role of autoantibodies and the benefit of therapeutic plasma exchange on a deadly lung disease.
UAB Hospital continues to be highly ranked by U.S. News and World Report, and is noted as the No. 1 hospital in Alabama.
A UAB physician will co-chair a steering committee of global cystic fibrosis experts and clinical trial investigators to support the design, conduct and execution of the triple combination pivotal study program.
Physicians at UAB share tips on men’s health and how it affects heart health, sexual function and memory and decreases cancer risk.
Eleven outstanding faculty members were named recipients of the 2017 Dean’s Excellence Awards, an honor recognizing exceptional contributions made by School of Medicine faculty in service, teaching, research, diversity enhancement and mentorship.
Successful Phase III trials at UAB contributed to the development of a novel “corrector-potentiator” combination drug therapy for cystic fibrosis patients.
As lung diseases worsen worldwide, UAB has launched a pre-doctoral training program in pulmonary research that will focus on lung diseases such as asthma, cancer, COPD, cystic fibrosis, pneumonia, lung injury and idiopathic pulmonary fibrosis.
Page 1 of 6